Kornimate/medical-research-clean huggingface dataset:
opera: french observational study on patients implanted with a guidant prizm or vitality defibrillator

Conditions: Ventricular Tachycardia; Ventricular Fibrillation

Summary: this study evaluates the date of the first appropriate and/or inappropriate therapy in patients implanted with a guidant prizm or vitality defibrillator and is evaluating eventual predictive risk factors for appropriate/inappropriate therapies as well as the influence of the programmed parameters on these therapies.

the registry measured the times to, and studied the determinants of, first appropriate (fat) and inappropriate (fit) therapy delivered by single, dual and triple chamber (crt-d) icd implanted for primary and secondary prevention indications.

Eligibility criteria:
inclusion criteria: * indication for an icd according to current guidelines, incl. prophylactic indication exclusion criteria: * pregnant or at birth bearing age without contraception, participation in another clinical trial, short life expectancy, geographically unstable for a follow-up at the investigational center
correlation between pet/ct parameters and tumor markers in recurrent breast cancer

Conditions: Breast Cancer

Summary: worldwide, breast cancer (bc) is the most frequent type of cancer in women yet, it is associated with relatively lower mortality rates, as it ranks fifth in cancer-related deaths overall, which is attributed to evolution in the treatment of recurrent and metastatic lesions, especially when these lesions were detected early . bc recurrence can occur even 15 years after primary treatment.

life-long routine monitoring is mandatory. although histopathologic confirmation is the definitive diagnostic method for bc recurrence, it is not always easy to perform as in cases with deeply located or very small-size lesions, or lesion too close to organs or great vessels, making sampling either inaccessible or hazardous. bc recurrence can be assessed using morphological imaging studies or tumor markers. mammography, ultrasound (us), computed tomography (ct), and magnetic resonance imaging (mri) are currently the most commonly used morphological imaging methods for detecting breast cancer recurrence. however, both of the two modalities have some restrictions. cancer antigen 15-3 (ca 15-3) and carcinoembryonic antigen (cea) are two tumor markers that are frequently used in the monitoring of bc patients . however, the findings of many studies on these markers in bc follow-up are conflicting. the introduction of integrated 2-deoxy-2-\[18 f\] fluoro-d-glucose (18fdg) positron emission tomography (pet) computed tomography (ct), known as pet/ct, has become a helpful tool for this purpose. pet/ct is the functional imaging tool that can measure increased glucose metabolism in cancer cells by using 18f-fdg. its ability to identify tumor recurrence before detection of morphologic changes in conventional imaging reflecting its importance in detecting bc recurrence in asymptomatic patients with high tumor markers and negative results of radiological imaging. 18f-fdg pet/ct is frequently used for bc evaluation. however, data on its value in evaluating bc recurrence in patients with elevated tumor markers are limited and unclear

Eligibility criteria:
inclusion criteria: * female patient with pathologically proved breast cancer who will be referred to do pet\\ct imaging at the nuclear medicine unit, assiut university hospital due to suspicion of recurrence based on elevated level of tumor marker in the period between october 2021 until the end of the study . exclusion criteria: * patients with newly diagnosed bc patients with early stages of bc bc patients with normal serum level of tumor markers
mcr syndrome in quebec : results from nuage study

Conditions: Motoric Cognitive Risk Syndrome; Aging Disorder

Summary: the overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (mcr) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the quebec elderly population. cognition and locomotion are two human abilities controlled by the brain. their decline is highly prevalent with physiological and pathological aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. both declines in cognition and locomotion are associated, furthermore the temporal nature of their association has been unclear for a long time. recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that mcr syndrome is a pre-dementia syndrome, suggesting that low gait performance is the first symptom of dementia. the uniqueness of mcr syndrome is that it does not rely on a complex evaluation or laboratory investigations. indeed, this syndrome combined subjective cognitive complaint and objective slow gait speed, and is easy to apply in population-based settings. prevalence and incidence of mcr syndrome, as well as its association with incidence of cognitive decline and impairment, have never been reported in canada. nutrition as a determinant of successful aging: the quebec longitudinal study (the nuage study) is a quebec population-based observational cohort study performed in healthy older community-dwellers adults which provides a unique opportunity to: 1) obtain reliable estimates of mcr syndrome prevalence and incidence, 2) determine the distribution of clinical and biological (blood biomarkers and genetic) characteristics associated with mcr syndrome, 3) examine the association of mcr syndrome and its biological characteristics with cognitive decline and incidence of cognitive impairment in the quebec elderly population.


Eligibility criteria:
inclusion criteria: * all included participants of nuage study exclusion criteria: * no information about cognitive complaint in nuage database * no measure of walking speed in nuage database * no follow-up completed in nuage database
effect of benoxinate hydrochloride eye drops on the premature infant pain profile score during retinopathy of prematurity screening

Conditions: Retinopathy of Prematurity

Summary: aims: to evaluate the effects of topical benoxinate hcl eye drops on the premature infant pain profile (pipp) scores in infants undergoing retinopathy of prematurity (rop) screening. methods: a randomized prospective double-masked cross-over trial was conducted on preterm infants screened for rop at least twice. dilated fundus examination was done in group a infants using the tear substitute eye drops and the second using the benoxinate hcl drops and the reversed order of drops for group b. video recording of the pulse oximeter monitor, the face and the body of the infant were analyzed by a single neonatology consultant for premature infant pain profile (pipp) scoring 1 minute before, during the examination of the first eye, 1 minute and 5 minutes after the conclusion of the examination of the second eye. the sound of the ophthalmologist on the video recordings indicating the time of the lid speculum insertion, the shining of the indirect ophthalmoscope light without indentation and the scleral indentation would aid in assessing the differences of the pipp indicators during each step of the examination.

aims: to evaluate the effects of topical benoxinate hcl eye drops on premature infant pain profile (pipp) scores in infants undergoing retinopathy of prematurity (rop) screening. methods: a randomized prospective double-masked cross-over trial was conducted on preterm infants screened for rop at least twice. dilated fundus examination was done in group a infants using the tear substitute eye drops and the second using the benoxinate hcl drops and the reversed order of drops for group b. video recording of the pulse oximeter monitor, the face and the body of the infant were analyzed by a single neonatology consultant for premature infant pain profile (pipp) scoring 1 minute before, during the examination of the first eye, 1 minute and 5 minutes after the conclusion of the examination of the second eye. the sound of the ophthalmologist on the video recordings indicating the time of the lid speculum insertion, the shining of the indirect ophthalmoscope light without indentation and the scleral indentation would aid in assessing the differences of the pipp indicators during each step of the examination.

Eligibility criteria:
inclusion criteria: * preterm infants with ga ≤34 weeks and/or with birth weight ≤2000 g * preterm infants with larger ga or birth weight who were at increased risk of rop according to the attending neonatologist * infants were believed to require at least 2 rop screenings exclusion criteria: * infants on muscle relaxants, analgesics, sedatives, or exogenous steroids * infants who required mechanical ventilation or continuous positive airway pressure at the first examination

Keywords: infant stress retinopathy of prematurity benoxinate hydrochloride pipp score
assessment of the efficacy of fosfomycin in patients with bacterial infection

Conditions: Bacterial Infection

Summary: this project aims to assess the clinical and microbiological efficacy of fosfomycin(fom) in patients with bacterial infection. primary objective: • to assess clinical and microbiological efficacy of fom in patients with bacterial infection. secondary objectives: * to determine the rate and severity of unexpected adverse events. * to determine the mean duration of therapy with fom in patients with bacterial infection. study design: multi-center, non-interventional study

please note that infectopharm arzneimittel und consilium gmbh has taken over sponsor responsibilities for all german sites of this clinical trial with jannuary 2016 from j\&p medical research ltd.

Eligibility criteria:
inclusion criteria: * patients with bacterial infection receiving fom for clinical purposes will be included into the analysis. exclusion criteria: -
spyral htn-on med study of renal denervation with the symplicity spyral™ multi-electrode renal denervation system

Conditions: Hypertension; Vascular Diseases; Cardiovascular Diseases

Summary: the purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.

the purpose of this study is to test the hypothesis that renal denervation is safe and reduces systolic blood pressure (sbp) in patients with uncontrolled hypertension on one, two, or three standard antihypertensive medications compared to a sham control in the same population. in this study, "uncontrolled hypertension" is defined as an office systolic blood pressure (sbp) ≥ 150 mmhg and \<180 mmhg, an office diastolic blood pressure (dbp) ≥90 mmhg and a 24-hour ambulatory blood pressure monitoring (abpm) average sbp ≥140 mmhg to \<170 mmhg, all of which are measured at screening visits. data obtained will be used to confirm the effect of renal denervation on elevated blood pressure in patients on 1, 2 or 3 antihypertensive medications.

Eligibility criteria:
inclusion criteria: * individual has office systolic blood pressure (sbp) ≥ 150 mmhg and \<180 mmhg and a diastolic blood pressure (dbp) ≥ 90 mmhg when receiving a medication regimen of one, two, or three antihypertensive medication classes. * individual has 24-hour ambulatory blood pressure monitoring (abpm) average sbp ≥ 140 mmhg and \< 170 mmhg. exclusion criteria: * individual lacks appropriate renal artery anatomy. * individual has estimated glomerular filtration rate (egfr) of \<45. * individual has type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus. * individual has one or more episodes of orthostatic hypotension. * individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. * individual has primary pulmonary hypertension. * individual is pregnant, nursing or planning to become pregnant. * individual has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (nsaids) for two or more days per week over the month prior to enrollment * individual has stable or unstable angina within 3 months of enrollment, myocardial infarction within 3 months of enrollment; heart failure, cerebrovascular accident or transient ischemic attack, or atrial fibrillation at any time. * individual works night shifts.

Keywords: uncontrolled hypertension renal denervation
efficacy of intra-auricular tranexamic acid in total knee arthroplasty

Conditions: Postoperative Hemorrhage

Summary: tranexamic acid an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin and many studies confirms its effectiveness in decreasing blood loss. the aim of this study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid in adult patients undergoing unilateral total knee replacement.

total knee arthroplasty (tka) is widely used as an effective treatment for end-stage osteoarthritis and other joint diseases of the knee and it improvements in surgical materials and techniques have greatly increased its effectiveness. however, tka is an orthopaedic surgical method that has a substantial perioperative blood loss. classical methods for reducing blood loss and transfusion rate include the use of a pneumatic tourniquet, intraoperative cell saver, hypotensive anesthesia, application of erythropoietin, autologous blood transfusion, plugging of the femoral canal, cementing, drain clamping, navigation and minimally invasive surgery. tranexamic acid (txa) an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin has been used as an adjuvant to such measure and many studies with a level of evidence confirms its effectiveness in decreasing blood loss. fibrinolysis is stimulated by surgical trauma blood loss and tka may be related to increased fibrinolytic activity. txa inhibits fibrinolysis by blocking the lysine-binding sites of plasminogen to fibrin. plasmin, bound to tranexamic acid, has a considerably diminished activity with respect to fibrin compared to that of free plasmin. also, it appears from various studies that, in vivo, tranexamic acid at high doses exerts a braking activity on the activation of the complement system. so, txa reduces bleeding in the tka and its functional repercussion has also been confirmed in assays for various dosages and routes of administration. in the literature, efficacy of intra-articular txa has also been confirmed, but what is the right dosage is now unclear. the aim of this study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid (sanofi-aventis® gentilly, france).

Eligibility criteria:
inclusion criteria: - adult patients undergoing unilateral total knee replacement exclusion criteria: * absence of consent * tranexamic acid allergy * coagulopathy (preoperative platelet count \ 1.4, or prolonged partial thromboplastin time\> 1.4 times normal), * history of arterial or venous thromboembolic disease (cerebrovascular accident, deep vein thrombosis or pulmonary thromboembolism), * hematological disorder (a hematopoietic, hemorrhagic or thrombogenic disease), * retinopathy (severe limitation of the field of vision and / or color distortion), * refusal to receive blood products * pregnancy * history of convulsions * participation in another clinical trial.
north american acute coronary syndrome (acs) reflective iii pilot

Conditions: Dyslipidemias; Acute Coronary Syndrome

Summary: the north american acs reflective iii pilot is an observational, quality enhancement research initiative (queri), knowledge translation program designed to give feedback to physicians on their post-acs lipid-lowering management in an effort to support their decision-making and choice of therapies and thereby better achieve evidence-based, guideline-recommended management of post-acs patients. the acs reflective iii pilot follows the completed acs registries i, ii, and iii, acs reflective i, and the ongoing acs reflective ii programs.

the main objectives are: 1. to identify and describe post-acs patients who do not achieve guideline-recommended ldl-c "target" (\ 50% ldl-c lowering on high-intensity statin in the u.s.); 2. to identify opportunities where pcsk9 inhibitor therapy may be of potential benefit in the management of post-acs patients to achieve guideline-recommended ldl-c goal by 1 year follow-up; and, 3. to determine reasons why physicians are not prescribing guideline-recommended ldl-c lowering therapies and/or patients are not achieving guideline-recommended ldl-c goals.

Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age; 2. acs 1-12 months prior to enrolment defined by symptoms of myocardial ischemia with an unstable pattern, occurring at rest or with minimal exertion, within 72 hours of an unscheduled hospital admission due to presumed or proven obstructive coronary disease and at least one of the following: 1. elevated cardiac biomarkers (e.g., troponin) = myocardial infarction (mi); or, 2. resting ecg changes consistent with ischemia, plus additional evidence of obstructive coronary disease from regional wall motion or perfusion abnormality, 70% or greater epicardial coronary stenosis by angiography, or need for coronary revascularization procedure = unstable angina (ua); and, 3. ldl-c ≥1.81 mmol/l (70 mg/dl) despite maximally tolerated statin ± ezetimibe therapy (including patients who are intolerant of ≥2 statins). exclusion criteria: 1. participating in a research study where the lipid-modifying therapy is unknown, randomly assigned (i.e., choice not determined by the physician), or not approved for clinical use; or 2. follow-up or life expectancy \<1 year.
reduction in macbar of sevoflurane by dexmedetomidine in children

Conditions: Children

Summary: the study was designed to define the interaction of intravenous infusion of dexmedetomidine, an a2-adrenergic agonist, and sevoflurane in children having surgery by using the minimum alveolar concentration which can block adrenergic and cardiovascular responses to incision(macbar) of sevoflurane as the measure of anesthetic potency.

the investigators observed the effects of different doses of dexmedetomidine on the minimum alveolar concentration of sevoflurane to blockade adrenergic response to surgical incision in 50% of children (macbar). and to explore the safety of use of dexmedetomidine in pediatric patients.

Eligibility criteria:
inclusion criteria: * aged 2 to 6 yr * american society of anesthesiologists i or ii * scheduled to have general anesthesia and to have skin incisions on the abdomen exclusion criteria: * anemia or abnormal preoperative electrolyte concentrations * a history of cardiovascular or central nervous system diseases * a history of pulmonary disease * known hepatic or renal disease * a body weight exceeding 50% of the upper limit of ideal body weight for height * taking drugs with cardiovascular or central nervous system effects * use of any experimental drug within the past 30 days * allergy to any drug that may be administered during the study * exposure to general anesthesia within the previous 7 days * second- or third-degree atrioventricular block * taking drugs preoperatively that would interfere with mac determination(e.g.,opioids or sedatives)

Keywords: dexmedetomidine sevoflurane mac bar drug interaction anesthesia
the relationship of body function, participation and quality of life in patients with burn: a longitudinal study

Conditions: Burn

Summary: the relationship of body function, participation and quality of life in patients with burn: a longitudinal study

early rehabilitation to partial-thickness and full-thickness dermal injury are of vital importance for burn patient. literature reviews have shown that burn patients experiences adl and quality of life (qol) difficulties. due to varied severity, the outcome and expression of each patient also differs. the limitation of body function may consequently affect social participation and qol thereafter.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of burn injuries admitted to burn center or followed in burn clinic * age \>14 * no mental diseases * understand written chinese or could complete the questionnaires with staff's assistance exclusion criteria: * died during or after hospitalization * refused to participate in the investigation * concurrent medical illness that affecting the subjectivity of post burn sequelae (ex. progressive muscular or mental diseases, trauma or seizure) * age \>74

Keywords: burn patient developmental disabilities body function participation quality of life longitudinal study
comparison of psychotherapy programs to treat panic disorder

Conditions: Anxiety Disorders; Panic Disorder; Agoraphobia

Summary: this study will determine the relative effectiveness of three psychotherapies in treating people with a panic disorder.

panic disorder (pd) is a debilitating anxiety disorder. it is characterized by unexpected and repeated episodes of intense fear, accompanied by serious physical symptoms, such as chest pain, heart palpitations, shortness of breath, dizziness, or abdominal stress. available treatments for pd include medication therapy and cognitive behavioral therapy (cbt), a type of psychotherapy that teaches people how to view panic attacks differently and how to reduce anxiety. approximately 30% of patients refuse medication, however, and nearly 50% do not achieve remission with cbt alone. therefore, there is a pressing need for additional non-pharmacologic treatment methods. panic-focused psychodynamic psychotherapy (pfpp) and applied relaxation training (art) are among some of the other available treatments for pd. during art, individuals are taught to relax their muscles while being exposed to increasingly frightening situations. pfpp combines elements of cbt with other, more extensive approaches aimed at determining the anxiety's origin and at finding ways to reduce it. this study will compare the effectiveness of pfpp, cbt, and art in treating pd. participants in this single blind study will be randomly assigned to receive pfpp, cbt, or art for 12 weeks. all participants will attend between 19 and 24 treatment sessions over the course of the study. upon completing the study, participants will attend monthly follow-up visits for an additional 12 months. participants assigned to art who have not responded by the end of treatment may opt to receive pfpp or cbt. outcomes will be assessed using a variety of scales to determine depression and anxiety symptoms.

Eligibility criteria:
inclusion criteria: * meets dsm-iv diagnosis criteria for primary pd with or without agoraphobia * history of at least one spontaneous panic attack per week within the month prior to study entry exclusion criteria: * active substance dependence within 6 months prior to study entry * lifetime history of any psychotic disorder, including bipolar disorder * acutely suicidal

Keywords: pd cbt pfpp
an 8-week, open-label, uncontrolled study of tamsulosin 0.4mg in men with bothersome urinary symptoms

Conditions: Lower Urinary Tract Symptoms

Summary: multicenter trial conducted in pharmacy retail centers


Eligibility criteria:
inclusion criteria: 1. men 18 years of age and older. 2. able to speak, read and understand english. 3. willing to participate in the study and voluntarily sign an informed consent document. exclusion criteria: 1. subject or anyone in their household is currently employed by a marketing or marketing research company, and advertising agency or public relations firm, a pharmacy or pharmaceutical company, a manufacturer of medicines, a managed care or health insurance company as a healthcare professional or healthcare practice.